Navigation Links
Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
Date:6/10/2013

BURLINGTON, Mass., June 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for platinum-resistant advanced ovarian cancer. The emerging agents for this indication—Roche/Genentech/Chugai's Avastin (which is already approved in Europe for recurrent platinum-sensitive ovarian cancer), Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and AstraZeneca's olaparib—are all expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled Ovarian Cancer (Platinum-Resistant Advanced): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need for This Difficult-to-Treat Patient Population?, finds that surveyed U.S. oncologists would prescribe Avastin in combination with either weekly paclitaxel (Bristol-Myers Squibb's Taxol, generics) or Janssen Biotech's Doxil/Caelyx to a total of 55 percent of their drug-treated patients with platinum-resistant advanced ovarian cancer.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in progression-free survival (PFS) in this patient population. Based on clinical data and thought-leader opinion, Avastin in combination with chemotherapy is in position to offer the PFS benefit that the majority of surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need," said Decision Resources Senior Analyst Gemma McConnell, Ph.D. "Current treatment consists of a non-platinum chemotherapy monotherapy, which typically result in low tumor response rates and a short progression-free interval. Taking together positive Phase III clinical data and interviewed experts' opinion, Avastin in combination with chemotherapy is poised to address this unmet need."

About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
2. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. NextDocs Launches QuickStart for Emerging Growth Companies
5. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
6. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
7. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
8. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
9. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
10. Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness
11. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, a trusted ... 17 Master's in Organizational Psychology Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/2/2019)... ... December 02, 2019 , ... Strong public health departments engaged ... and play. Striving to fulfill their crucial mission, more and more health departments ... the Public Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial ...
(Date:11/30/2019)... , ... November 29, 2019 , ... In the United ... With countless awards, reviews, and media, there is no shortage of phenomenal restaurants for ... the most exceptional talent in the world. Christian Bowman, Chef to NBA All-Stars and ...
Breaking Medicine Technology:
(Date:12/8/2019)... ... December 07, 2019 , ... Intelligent.com, a trusted resource ... Best Master of Science in Nursing (MSN) Degree Programs for 2020. The comprehensive ... in the nation. Each program is evaluated based on curriculum quality, graduation rate, ...
(Date:12/6/2019)... SAN JOSE, Calif. (PRWEB) , ... December 06, ... ... entering into the era of assembling and manufacturing implantable medical devices, which is ... , As the name suggests, implantable medical devices are surgically inserted into ...
(Date:12/6/2019)... ... ... for Tots to Give Free Toys to Children in Need , Dr. Alexis Parker, MD ... Lasair Aesthetic Health is spreading holiday cheer again this year by sponsoring the Toys for ... more than 25-dollars, will get FIVE units of Botox (a $60 value) for free from ...
(Date:12/6/2019)... ... ... Dr. Scott Howell, a 2019 graduate of Trident University International’s (Trident) Ph.D. ... oil in the 7 November 2019 edition of Progress in Cardiovascular Diseases . ... Review,” led by Dr. Hector O. Santos, examines the effect of coconut oil intake ...
(Date:12/5/2019)... ... December 05, 2019 , ... Intelligent.com, a trusted resource for ... Degree Programs for 2020. The comprehensive research guide is based on an assessment ... based on curriculum quality, graduation rate, reputation, and post-graduate employment. , The ...
Breaking Medicine News(10 mins):